Other
Olverembatinib
0
Pipeline Programs↗
6
Active Trials↗
1
Companies Involved↗
Olverembatinib is an early-stage landscape with 0 programs across 1 company. The most active players are Ascentage Pharma Group Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
11
clinical trials
Recruiting5 · 45%
Unknown status3 · 27%
Completed1 · 9%
Available1 · 9%
Not yet recruiting1 · 9%
Clinical Trials
Trial Activity
11 trials
Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT06757855·29 enrolled
A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05931757·22 enrolled
A Study of Olverembatinib in the Treatment of Ph+ ALL
Unknown status·—·Phase 2·NCT05466175·55 enrolled
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT05603156·46 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)